在全球范围内，癌症一直是威胁人类健康的重大疾病，其中结直肠癌（Colorectal cancer，CRC）更是 “名列前茅”，它不仅是全球癌症相关死亡的主要原因之一，也是胃肠道癌症中最常见的类型。大约 10% 的 CRC 患者存在 BRAF 突变，而 V600E 突变又是其中最为常见的类型。携带 BRAF 突变的 CRC ...

Researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a ...

为解决癌细胞对现有蛋白激酶抑制剂耐药及 BRAF 抑制剂研发难题，研究人员开展 1 - 取代 - 5,6 - 二氯苯并咪唑类化合物作为 BRAF WT/V600E 抑制剂的研究。发现化合物 10h 抗癌活性强，该成果为抗癌药物研发提供新方向，值得科研人员一读。 在细胞的世界里，有一条 ...

根据国内临床试验进展，Insight 数据库推测适应症为联合治疗 BRAF V600E 突变转移性非小细胞肺癌（NSCLC）。 恩考芬尼是一款 BRAF 抑制剂，比美替尼是 ...

New York, USA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- BRAF Inhibitors Market to Register Incremental Growth During the Study Period (2020–2034) | DelveInsight The BRAF Inhibitors market is expected to grow ...

The overactive BRAF protein now looked like an attractive drug target. Professors David Barford and Marais at the ICR made an important scientific step by elucidating the detailed molecular structure ...

Researchers at the University of California San Diego have uncovered a key mechanism underlying the treatment resistance of melanoma with the BRAF V600E mutation through pathways involved ... However, ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF genes (RAS/BRAF wild-type) are typically treated with EGFR inhibitors.

or MEK inhibitors such as selumetinib (AZD6244). Since trials investigating the potential use of anti-BRAF agents in the management of gliomas are ongoing, it cannot be excluded, in case of ...